Video

Educated Patient® Lung Cancer Summit Basics of Lung Cancer Session: August 14, 2021

Author(s):

CURE Media Group

View the full CURE Educated Patient Lung Cancer Summit on demand.

Related Videos
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with dark hair, smiling.
Image of woman with brown hair.
Image of man with grey hair.
Image of woman with black hair.
Related Content
Image of solid tumor makeup.
January 20th 2025

The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors

Ryan Scott
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lung cancer.
January 15th 2025

The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care

Ryan Scott
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of lungs.
January 11th 2025

FDA Grants Fast Track Designation for Abenacianine in Lung Cancer Surgery

Spencer Feldman
The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.